| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Buy our financial projections templates at Projection Hub. We provide financial forecasting and cash flow projection through our software and templates for investors, business plans, and loan applications. Learn about our financial projections template...
PowerReviews works with more than 1,000 global brands and retailers to deliver cloud-based software that collects and displays ratings and reviews and questions and answers on websites. Ratings and reviews solutions from PowerReviews are essential for consumers as they search and shop online and in-store, and they are proven to increase online site-wide sales.
ClearFocus Technologies provides innovative solutions to secure, improve and enable our client’s mission. Through our talented people and enabling technologies, we provide transformative solutions that improve the well-being of our clients while prote...
The Canadian Email Marketing software built for CASL that will bring you peace of mind. Create stunning newsletters in minutes. Create your free account!